Abivax increases size of Nasdaq uplisting deal
Abivax S.A. (FR:ABVX) has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol "ABVX" from Euronext Paris, according to a filing late Wednesday. Abivax plans to raise about $250 million with underwriters Morgan Stanley and Leerink at an estimated price range of $11.60 a share to $13 a share. The stock is expected to begin trading on Friday on the Nasdaq, according to IPOScoop.com. The deal will result in newly-listed stock on the Nasdaq, but it's not technically an initial public offering. Abivax is a clinical stage biotechnology company with a drug, obefazimod, in Phase III trials to treat ulcerative colitis. The company is offering American depositary shares in the U.S. and selling additional shares through a private placement in Europe.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-19-23 0648ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage